Evommune, Inc.(EVMN)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Evommune, Inc. (EVMN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EVMN at 14.9/100 on a 32-signal composite quality model, placing it at rank #2,859 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (2.1) and free cash flow (2.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Evommune, Inc. reports net income of $-32.2M, free cash flow of $-20.5M. Top institutional holders of EVMN by reported 13-F value include EQT Fund Management S.a r.l., RA CAPITAL MANAGEMENT, L.P., PRICE T ROWE ASSOCIATES, based on the most recent SEC filings. EVMN trades on the NYSE exchange and files with the SEC under CIK 2044725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EVMN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Evommune, Inc. directly from SEC EDGAR.